Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Slides:

Advertisements

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Advertisements

Figure 1 Ischaemic endpoints

Fig 1 The CONSORT participant flow diagram for primary endpoints.

Figure 1 Study flow chart.

From: Learning by Working in Big Cities

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

Fig. 1 Nodes in a conceptual knowledge graph

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

ADAb: anti-drug antibody.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Figure 1 Hazard ratios as a function of annual mean PM2

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Flow chart of patient enrollment and exclusion

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Figure 1 The occurrence of maternal cardiovascular events for the different diagnosis groups. AOP, aortic pathology; ... Figure 1 The occurrence of maternal.

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.

Fig. 1 Mean change from baseline in ANC ± s. e

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.

Fig. 1 Flow chart of included patients for analyses

Figure 1. Analysis of human TRIM5α protein with Blast-Search and PhyML+SMS ‘One click’ workflow. (A) NGPhylogeny.fr ... Figure 1. Analysis of human TRIM5α.

Figure 2. Natural history of chlamydia transmission, with arrows showing the transitions between health states. Figure 2. Natural history of chlamydia.

Fig. 1 Flow chart for selection of study subjects

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. A, Crude incidence rates per 100 person-years of follow-up and 95% confidence intervals for each solid organ ... Figure 1. A, Crude incidence.

FIGURE 1 Study consort diagram

Fig. 2 Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, ... Fig. 2 Case 2. Levels of serum.

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Illustration of DGR systems and their prediction using myDGR

FIGURE 1 Food groups consumed (mean, g/d) among US infants and young children by age group and tertile of mean ... FIGURE 1 Food groups consumed (mean,

Figure 1 Study flowchart and patient flow

Figure 4. Levels of cerebrospinal fluid (CSF) immune and inflammatory markers in participants grouped by CSF human ... Figure 4. Levels of cerebrospinal.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.

Figure 1. Uncertainty reduction, value creation, and appropriation in two case studies. Unless provided in the caption above, the following copyright applies.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1. The framework of NetGO with seven steps

Figure 1 Patient disposition

Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.

Figure 1 BM community in the normozoospermic and iNOA human testis parenchyma. Quantification of the 16 S copies/ng in ... Figure 1 BM community in the.

Figure 1. Trial profile. (A) Part A and (B) part B

Figure 1 Distribution of WCD use days in WEARIT-II

Figure 1. Excess cost of methicillin-resistant Staphylococcus aureus (MRSA) compared with methicillin-susceptible S. ... Figure 1. Excess cost of methicillin-resistant.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced.

Figure 1. Prevalence of parasitic infection and anemia among the children. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. GWAS Catalog associations for coronary artery disease plotted across all chromosomes. Associations added ... Figure 1. GWAS Catalog associations.

Source:Zimnisky (2014). Source:Zimnisky (2014).

Figure 1 Mechanisms of mitral regurgitation.

Figure 1 ABCDE of primary prevention.2

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Presentation transcript:

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Eur Heart J, Volume 40, Issue 2, 28 December 2018, Pages 180–186, https://doi.org/10.1093/eurheartj/ehy812 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2 Primary composite endpoint of cardiac death or myocardial infarction. The cumulative incidence of the primary ... Figure 2 Primary composite endpoint of cardiac death or myocardial infarction. The cumulative incidence of the primary endpoint of cardiac death or myocardial infarction was significantly reduced in subjects randomized to fractional flow reserve-guided percutaneous coronary intervention compared with medical therapy alone. Dashed lines are crude time-to-event curves and solid lines are fitted cumulative incidence curves as predicted from a mixed effects flexible parametric model. Only the fitted curves should be used for inferences about the treatment effect. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Eur Heart J, Volume 40, Issue 2, 28 December 2018, Pages 180–186, https://doi.org/10.1093/eurheartj/ehy812 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3 Subgroup analyses of primary composite endpoint of cardiac death or myocardial infarction. Pre-specified ... Figure 3 Subgroup analyses of primary composite endpoint of cardiac death or myocardial infarction. Pre-specified subgroup analyses of the primary outcome are shown according to clinical presentation (stable coronary artery disease vs. acute coronary syndrome) and fractional flow reserve status (patients with at least one stable coronary lesion with a positive fractional flow reserve of ≤0.80 vs. patients with only lesions with a negative fractional flow reserve of >0.80). The Post hoc subgroup analyses of the primary endpoint specified are shown according to age (>60 years or ≤60 years), sex, diabetes status, previous myocardial infarction, and smoking. CAD, coronary artery disease; FFR, fractional flow reserve; HR, hazard ratio; MT, medical therapy; PCI, percutaneous coronary intervention. P-values for interaction are for within-trial interaction unless indicated otherwise. *P-value for interaction is for across-trial interaction. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Eur Heart J, Volume 40, Issue 2, 28 December 2018, Pages 180–186, https://doi.org/10.1093/eurheartj/ehy812 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 4 Landmark analyses of primary composite endpoint and its components. The hazard ratios of the primary ... Figure 4 Landmark analyses of primary composite endpoint and its components. The hazard ratios of the primary composite outcome of cardiac death or myocardial infarction and of components of the primary composite outcome shown according to the time from randomization (7 days or less vs. 8 days or more). The solid boxes represent hazard ratios for 7 days or less after randomization, the open boxes represent hazard ratios for 8 days or more from randomization. Arrows indicate that the ends of the confidence interval are either less than 0.4 or more than 5. FFR, fractional flow reserve; HR, hazard ratio; PCI, percutaneous coronary intervention. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Eur Heart J, Volume 40, Issue 2, 28 December 2018, Pages 180–186, https://doi.org/10.1093/eurheartj/ehy812 The content of this slide may be subject to copyright: please see the slide notes for details.